Robert W. Duggan - 21 Oct 2025 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Role
Co-Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Robert W. Duggan
Issuer symbol
SMMT
Transactions as of
21 Oct 2025
Transactions value $
$267,499,951
Form type
4
Filing time
23 Oct 2025, 16:08:30 UTC
Previous filing
11 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DUGGAN ROBERT W Co-Chief Executive Officer, Director, 10%+ Owner C/O SUMMIT THERAPEUTICS INC., 601 BRICKELL KEY DRIVE SUITE 1000, MIAMI /s/ Robert W. Duggan 23 Oct 2025 0001055919

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SMMT Common Stock Award $262M +14M +2.51% $18.74 570M 21 Oct 2025 Direct F1
transaction SMMT Common Stock Award $5M +267K +1.05% $18.74 25.7M 21 Oct 2025 By the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee F1, F2
transaction SMMT Common Stock Purchase $500K +26.7K +53.36% $18.74 76.7K 21 Oct 2025 Immediate family member of Spouse F1, F2
holding SMMT Common Stock 31K 21 Oct 2025 By Spouse F2
holding SMMT Common Stock 10.2M 21 Oct 2025 By the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025.
F2 The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.